You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameBenzylpenicilloyl Polylysine
Accession NumberDB00895  (APRD00822)
TypeSmall Molecule
GroupsApproved
DescriptionBenzylpenicilloyl Polylysine is used as a skin-testing reagent to detect immunoglobulin E antibodies in people with a history of penicillin allergy. The quantitation of in vitro IgE antibodies to the benzylpenicilloyl determinant is a useful tool for evaluating allergic subjects.
Structure
Thumb
Synonyms
Benzyl penicilloyl-polylysine
Benzylpenicilloyl G polylysine
Benzylpenicilloyl-polylysine
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Pre-penInjection60 umol/.25mLIntradermal; SubcutaneousAller Quest Llc1974-07-25Not applicableUs
Pre-penSolution0.000060 mIntradermalAlk Abello Inc1975-12-31Not applicableCanada
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International BrandsNot Available
Brand mixturesNot Available
SaltsNot Available
Categories
UNII76479814OY
CAS number31855-75-1
WeightAverage: 626.765
Monoisotopic: 626.309783168
Chemical FormulaC28H46N6O8S
InChI KeyIMPVZRLKKKXMKQ-SGDOCVTFSA-N
InChI
InChI=1S/C22H32N4O6S.C6H14N2O2/c1-22(2)17(21(31)32)26-19(33-22)16(25-15(27)12-13-8-4-3-5-9-13)18(28)24-11-7-6-10-14(23)20(29)30;7-4-2-1-3-5(8)6(9)10/h3-5,8-9,14,16-17,19,26H,6-7,10-12,23H2,1-2H3,(H,24,28)(H,25,27)(H,29,30)(H,31,32);5H,1-4,7-8H2,(H,9,10)/t14-,16?,17+,19-;5-/m11/s1
IUPAC Name
SMILES
Pharmacology
IndicationFor use as a adjunct in assessing the risk of administering penicillin (benzylpenicillin or penicillin G).
Structured Indications
PharmacodynamicsBenylpenicilloyl polylysine is penicilloyl bound to polylysine and is considered to be the major determinant of penicillin metabolism; it is used as a skin-testing reagent to detect immunoglobulin E antibodies in people with a history of penicillin allergy. If skin testing using benzylpenicilloyl and penicillin G (as the sole source of minor determinants) is negative, approximately 97% of patients with a negative skin test will tolerate penicillin.
Mechanism of actionThe skin test for penicillin demonstrates the presence or absence of specific IgE antibodies to major and minor penicillin determinants. IgE antibodies to major determinants can be detected by using benzylpenicilloyl polylysine. A penicillin skin test predicts only the presence of IgE antibodies for the major or minor penicillin determinants at the time of application and does not predict the future development of IgE-mediated reactions during subsequent courses of penicillin. Benzylpenicilloyl polylysine reacts specifically with penicilloyl skin sensitizing antibodies (reagins) to produce immediate wheal and flare reactions which may reflect increased risk of allergic reactions to subsequent penicillin therapy.
TargetKindPharmacological actionActionsOrganismUniProt ID
High affinity immunoglobulin epsilon receptor subunit gammaProteinyes
agonist
HumanP30273 details
High affinity immunoglobulin epsilon receptor subunit alphaProteinyes
agonist
HumanP12319 details
Related Articles
AbsorptionNot Available
Volume of distributionNot Available
Protein bindingNot Available
MetabolismNot Available
Route of eliminationNot Available
Half lifeNot Available
ClearanceNot Available
ToxicitySymptoms of overdose include urticaria, generalized pruritus, local swelling, generalized flushing, anaphylaxis, bronchospasm, fainting and maculopapular eruption.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
AcenocoumarolBenzylpenicilloyl Polylysine may increase the anticoagulant activities of Acenocoumarol.Approved
AclarubicinThe serum concentration of Aclarubicin can be decreased when it is combined with Benzylpenicilloyl Polylysine.Investigational
AcrivastineAcrivastine may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Approved
AdrafinilAdrafinil may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Withdrawn
AlcaftadineAlcaftadine may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Approved
AlimemazineAlimemazine may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Approved, Vet Approved
AmikacinThe serum concentration of Amikacin can be decreased when it is combined with Benzylpenicilloyl Polylysine.Approved, Vet Approved
AmitrazAmitraz may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Vet Approved
AmrubicinThe serum concentration of Amrubicin can be decreased when it is combined with Benzylpenicilloyl Polylysine.Approved, Investigational
AnisodamineAnisodamine may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Investigational
annamycinThe serum concentration of annamycin can be decreased when it is combined with Benzylpenicilloyl Polylysine.Investigational
AntazolineAntazoline may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Approved
ApraclonidineApraclonidine may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Approved
ApramycinThe serum concentration of Apramycin can be decreased when it is combined with Benzylpenicilloyl Polylysine.Experimental, Vet Approved
ArbekacinThe serum concentration of Arbekacin can be decreased when it is combined with Benzylpenicilloyl Polylysine.Approved
ArbutamineArbutamine may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Approved
ArformoterolArformoterol may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Approved, Investigational
AstemizoleAstemizole may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Approved, Withdrawn
AzatadineAzatadine may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Approved
AzelastineAzelastine may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Approved
BefunololBefunolol may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Experimental
BitolterolBitolterol may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Withdrawn
BrimonidineBrimonidine may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Approved
BrompheniramineBrompheniramine may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Approved
BuclizineBuclizine may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Approved
Butanoic AcidButanoic Acid may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Experimental
CarbinoxamineCarbinoxamine may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Approved
CetirizineCetirizine may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Approved
ChloropyramineChloropyramine may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Approved
ChlorphenamineChlorphenamine may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Approved
ChlorphenoxamineChlorphenoxamine may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Withdrawn
ChlortetracyclineThe therapeutic efficacy of Benzylpenicilloyl Polylysine can be decreased when used in combination with Chlortetracycline.Approved, Vet Approved
CimetidineCimetidine may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Approved
CinnarizineCinnarizine may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Approved
CirazolineCirazoline may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Experimental
ClemastineClemastine may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Approved
ClenbuterolClenbuterol may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Approved, Vet Approved
ClonidineClonidine may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Approved
CyclizineCyclizine may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Approved
CyproheptadineCyproheptadine may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Approved
DaunorubicinThe serum concentration of Daunorubicin can be decreased when it is combined with Benzylpenicilloyl Polylysine.Approved
DemeclocyclineThe therapeutic efficacy of Benzylpenicilloyl Polylysine can be decreased when used in combination with Demeclocycline.Approved
DesloratadineDesloratadine may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Approved, Investigational
DetomidineDetomidine may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Vet Approved
DexbrompheniramineDexbrompheniramine may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Approved
Dexchlorpheniramine maleateDexchlorpheniramine maleate may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Approved
DexmedetomidineDexmedetomidine may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Approved, Vet Approved
DicoumarolBenzylpenicilloyl Polylysine may increase the anticoagulant activities of Dicoumarol.Approved
DihydrostreptomycinThe serum concentration of Dihydrostreptomycin can be decreased when it is combined with Benzylpenicilloyl Polylysine.Vet Approved
DimenhydrinateDimenhydrinate may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Approved
DimetindeneDimetindene may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Approved
DimetotiazineDimetotiazine may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Approved
DiphenhydramineDiphenhydramine may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Approved
DipivefrinDipivefrin may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Approved
DobutamineDobutamine may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Approved
DoxepinDoxepin may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Approved
DoxorubicinThe serum concentration of Doxorubicin can be decreased when it is combined with Benzylpenicilloyl Polylysine.Approved, Investigational
DoxycyclineThe therapeutic efficacy of Benzylpenicilloyl Polylysine can be decreased when used in combination with Doxycycline.Approved, Investigational, Vet Approved
DoxylamineDoxylamine may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Approved, Vet Approved
DroxidopaDroxidopa may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Approved, Investigational
EbastineEbastine may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Investigational
EmedastineEmedastine may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Approved
EphedrineEphedrine may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Approved
EpinastineEpinastine may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Approved, Investigational
EpinephrineEpinephrine may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Approved, Vet Approved
EpirubicinThe serum concentration of Epirubicin can be decreased when it is combined with Benzylpenicilloyl Polylysine.Approved
ErgotamineErgotamine may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Approved
EsmirtazapineEsmirtazapine may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Investigational
EthopropazineEthopropazine may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Approved
Ethyl biscoumacetateBenzylpenicilloyl Polylysine may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
EtilefrineEtilefrine may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Withdrawn
FamotidineFamotidine may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Approved
FenoterolFenoterol may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Approved
FexofenadineFexofenadine may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Approved
FluindioneBenzylpenicilloyl Polylysine may increase the anticoagulant activities of Fluindione.Investigational
FlunarizineFlunarizine may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Approved
FormoterolFormoterol may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Approved, Investigational
FramycetinThe serum concentration of Framycetin can be decreased when it is combined with Benzylpenicilloyl Polylysine.Approved
GeneticinThe serum concentration of Geneticin can be decreased when it is combined with Benzylpenicilloyl Polylysine.Experimental
GentamicinThe serum concentration of Gentamicin can be decreased when it is combined with Benzylpenicilloyl Polylysine.Approved, Vet Approved
GENTAMICIN C1AThe serum concentration of GENTAMICIN C1A can be decreased when it is combined with Benzylpenicilloyl Polylysine.Experimental
GuanabenzGuanabenz may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Approved
GuanfacineGuanfacine may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Approved, Investigational
HexoprenalineHexoprenaline may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Approved, Withdrawn
HigenamineHigenamine may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Investigational
HydroxyzineHydroxyzine may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Approved
Hygromycin BThe serum concentration of Hygromycin B can be decreased when it is combined with Benzylpenicilloyl Polylysine.Vet Approved
IdarubicinThe serum concentration of Idarubicin can be decreased when it is combined with Benzylpenicilloyl Polylysine.Approved
INNO-206The serum concentration of INNO-206 can be decreased when it is combined with Benzylpenicilloyl Polylysine.Investigational
IsoetarineIsoetarine may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Approved
IsoprenalineIsoprenaline may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Approved
IsothipendylIsothipendyl may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Approved
IsoxsuprineIsoxsuprine may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Approved, Withdrawn
KanamycinThe serum concentration of Kanamycin can be decreased when it is combined with Benzylpenicilloyl Polylysine.Approved, Vet Approved
Kct 0809Kct 0809 may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Investigational
KetotifenKetotifen may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Approved
LevocabastineLevocabastine may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Approved
LevocetirizineLevocetirizine may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Approved
LodoxamideLodoxamide may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Approved
LofexidineLofexidine may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Approved, Investigational
LoratadineLoratadine may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Approved
MeclizineMeclizine may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Approved
MedetomidineMedetomidine may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Vet Approved
MephentermineMephentermine may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Approved
MepyramineMepyramine may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Approved, Vet Approved
MequitazineMequitazine may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Approved
MetaraminolMetaraminol may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Approved, Investigational
MethapyrileneMethapyrilene may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Withdrawn
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Benzylpenicilloyl Polylysine.Approved
MethoxamineMethoxamine may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Approved
MethyldopaMethyldopa may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Approved
MetiamideMetiamide may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Experimental
MetrizamideThe serum concentration of Metrizamide can be decreased when it is combined with Benzylpenicilloyl Polylysine.Approved
MianserinMianserin may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Approved
MidodrineMidodrine may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Approved
MinocyclineThe therapeutic efficacy of Benzylpenicilloyl Polylysine can be decreased when used in combination with Minocycline.Approved, Investigational
MirabegronMirabegron may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Approved
MirtazapineMirtazapine may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Approved
MizolastineMizolastine may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Investigational
Mycophenolic acidThe serum concentration of the active metabolites of Mycophenolic acid can be reduced when Mycophenolic acid is used in combination with Benzylpenicilloyl Polylysine resulting in a loss in efficacy.Approved
NaphazolineNaphazoline may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Approved
NeamineThe serum concentration of Neamine can be decreased when it is combined with Benzylpenicilloyl Polylysine.Experimental
NebivololNebivolol may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Approved, Investigational
NeomycinThe serum concentration of Neomycin can be decreased when it is combined with Benzylpenicilloyl Polylysine.Approved, Vet Approved
NetilmicinThe serum concentration of Netilmicin can be decreased when it is combined with Benzylpenicilloyl Polylysine.Approved
NizatidineNizatidine may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Approved
NorepinephrineNorepinephrine may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Approved
NylidrinNylidrin may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Approved
OlodaterolOlodaterol may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Approved
OlopatadineOlopatadine may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Approved
OrciprenalineOrciprenaline may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Approved
OxymetazolineOxymetazoline may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Approved
OxytetracyclineThe therapeutic efficacy of Benzylpenicilloyl Polylysine can be decreased when used in combination with Oxytetracycline.Approved, Vet Approved
ParomomycinThe serum concentration of Paromomycin can be decreased when it is combined with Benzylpenicilloyl Polylysine.Approved, Investigational
PemirolastPemirolast may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Approved
PhenindaminePhenindamine may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Approved
PhenindioneBenzylpenicilloyl Polylysine may increase the anticoagulant activities of Phenindione.Approved
PheniraminePheniramine may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Approved
PhenprocoumonBenzylpenicilloyl Polylysine may increase the anticoagulant activities of Phenprocoumon.Approved
PhenylephrinePhenylephrine may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Approved
PhenylpropanolaminePhenylpropanolamine may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Approved, Vet Approved, Withdrawn
PirarubicinThe serum concentration of Pirarubicin can be decreased when it is combined with Benzylpenicilloyl Polylysine.Investigational
PirbuterolPirbuterol may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Approved
PlicamycinThe serum concentration of Plicamycin can be decreased when it is combined with Benzylpenicilloyl Polylysine.Approved, Withdrawn
ProbenecidThe serum concentration of Benzylpenicilloyl Polylysine can be increased when it is combined with Probenecid.Approved
ProcaterolProcaterol may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Approved
PromethazinePromethazine may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Approved
PseudoephedrinePseudoephedrine may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Approved
PuromycinThe serum concentration of Puromycin can be decreased when it is combined with Benzylpenicilloyl Polylysine.Experimental
RacepinephrineRacepinephrine may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Approved
RactopamineRactopamine may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Vet Approved
RanitidineRanitidine may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Approved
RibostamycinThe serum concentration of Ribostamycin can be decreased when it is combined with Benzylpenicilloyl Polylysine.Approved
RilmenidineRilmenidine may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Investigational
RitobegronRitobegron may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Investigational
RitodrineRitodrine may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Approved
RomifidineRomifidine may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Vet Approved
Roxatidine acetateRoxatidine acetate may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Approved
SalbutamolSalbutamol may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Approved, Vet Approved
SalmeterolSalmeterol may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Approved
SisomicinThe serum concentration of Sisomicin can be decreased when it is combined with Benzylpenicilloyl Polylysine.Investigational
SolabegronSolabegron may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Investigational
SP1049CThe serum concentration of SP1049C can be decreased when it is combined with Benzylpenicilloyl Polylysine.Investigational
Spaglumic AcidSpaglumic Acid may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Approved
SpectinomycinThe serum concentration of Spectinomycin can be decreased when it is combined with Benzylpenicilloyl Polylysine.Approved, Vet Approved
SR 58611SR 58611 may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Investigational
StreptomycinThe serum concentration of Streptomycin can be decreased when it is combined with Benzylpenicilloyl Polylysine.Approved, Vet Approved
StreptozocinThe serum concentration of Streptozocin can be decreased when it is combined with Benzylpenicilloyl Polylysine.Approved
SynephrineSynephrine may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Experimental
TerbutalineTerbutaline may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Approved
TerfenadineTerfenadine may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Withdrawn
TesmilifeneTesmilifene may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Investigational
TetracyclineThe therapeutic efficacy of Benzylpenicilloyl Polylysine can be decreased when used in combination with Tetracycline.Approved, Vet Approved
ThonzylamineThonzylamine may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Approved
TizanidineTizanidine may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Approved
TobramycinThe serum concentration of Tobramycin can be decreased when it is combined with Benzylpenicilloyl Polylysine.Approved, Investigational
TranilastTranilast may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Approved, Investigational
TripelennamineTripelennamine may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Approved, Vet Approved
TriprolidineTriprolidine may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Approved
TulobuterolTulobuterol may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Investigational
ValrubicinThe serum concentration of Valrubicin can be decreased when it is combined with Benzylpenicilloyl Polylysine.Approved
WarfarinBenzylpenicilloyl Polylysine may increase the anticoagulant activities of Warfarin.Approved
XylazineXylazine may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Vet Approved
YM-178YM-178 may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Investigational
ZorubicinThe serum concentration of Zorubicin can be decreased when it is combined with Benzylpenicilloyl Polylysine.Experimental
Food InteractionsNot Available
References
Synthesis ReferenceNot Available
General ReferencesNot Available
External Links
ATC CodesNot Available
AHFS Codes
  • 36:30.00
PDB EntriesNot Available
FDA labelNot Available
MSDSNot Available
ADMET
Predicted ADMET featuresNot Available
Pharmacoeconomics
Manufacturers
  • Allerquest llc
Packagers
Dosage forms
FormRouteStrength
InjectionIntradermal; Subcutaneous60 umol/.25mL
SolutionIntradermal0.000060 m
Prices
Unit descriptionCostUnit
Pre-pen ampul72.0USD ampul
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
logP-0.8Not Available
Predicted Properties
PropertyValueSource
logP-3.8ChemAxon
Hydrogen Acceptor Count8ChemAxon
Hydrogen Donor Count6ChemAxon
Polar Surface Area170.85 Å2ChemAxon
Rotatable Bond Count17ChemAxon
Refractivity122.22 m3·mol-1ChemAxon
Polarizability50.05 Å3ChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as n-acyl-alpha amino acids and derivatives. These are compounds containing an alpha amino acid (or a derivative thereof) which bears an acyl group at its terminal nitrogen atom.
KingdomOrganic compounds
Super ClassOrganic acids and derivatives
ClassCarboxylic acids and derivatives
Sub ClassAmino acids, peptides, and analogues
Direct ParentN-acyl-alpha amino acids and derivatives
Alternative Parents
Substituents
  • N-acyl-alpha amino acid or derivatives
  • Alpha-amino acid amide
  • Beta amino acid or derivatives
  • D-alpha-amino acid
  • Phenylacetamide
  • Alpha-amino acid
  • Medium-chain fatty acid
  • Heterocyclic fatty acid
  • Amino fatty acid
  • Fatty acyl
  • Fatty acid
  • Benzenoid
  • Dicarboxylic acid or derivatives
  • Monocyclic benzene moiety
  • Thiazolidine
  • Secondary carboxylic acid amide
  • Carboxamide group
  • Azacycle
  • Organoheterocyclic compound
  • Dialkylthioether
  • Hemithioaminal
  • Thioether
  • Secondary amine
  • Secondary aliphatic amine
  • Carboxylic acid
  • Carboxylic acid amide
  • Hydrocarbon derivative
  • Primary amine
  • Organooxygen compound
  • Organonitrogen compound
  • Primary aliphatic amine
  • Carbonyl group
  • Amine
  • Aromatic heteromonocyclic compound
  • Aliphatic acyclic compound
Molecular FrameworkNot Available
External Descriptors

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
agonist
General Function:
Igg binding
Specific Function:
Associates with a variety of FcR alpha chains to form a functional signaling complex. Regulates several aspects of the immune response. The gamma subunit has a critical role in allowing the IgE Fc receptor to reach the cell surface. Also involved in collagen-mediated platelet activation and in neutrophil activation mediated by integrin.
Gene Name:
FCER1G
Uniprot ID:
P30273
Molecular Weight:
9667.355 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Chandra RK, Joglekar SA, Tomas E: Penicillin allergy: anti-penicillin IgE antibodies and immediate hypersensitivity skin reactions employing major and minor determinants of penicillin. Arch Dis Child. 1980 Nov;55(11):857-60. [PubMed:7436456 ]
  4. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
agonist
General Function:
Ige receptor activity
Specific Function:
Binds to the Fc region of immunoglobulins epsilon. High affinity receptor. Responsible for initiating the allergic response. Binding of allergen to receptor-bound IgE leads to cell activation and the release of mediators (such as histamine) responsible for the manifestations of allergy. The same receptor also induces the secretion of important lymphokines.
Gene Name:
FCER1A
Uniprot ID:
P12319
Molecular Weight:
29595.67 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Chandra RK, Joglekar SA, Tomas E: Penicillin allergy: anti-penicillin IgE antibodies and immediate hypersensitivity skin reactions employing major and minor determinants of penicillin. Arch Dis Child. 1980 Nov;55(11):857-60. [PubMed:7436456 ]
  4. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23